Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
TipRanks on MSN
SinoMab’s SM17 IND application for IBD accepted by NMPA
An update from SinoMab Bioscience Ltd. ( ($HK:3681) ) is now available. SinoMab BioScience Limited announced that its Investigational New Drug ...
Discover how in silico tools can be used can be used with organ-on-a-chip for the advancement of ADME studies.
Streamlined pharmacologic recommendations challenge the stepwise approach for moderately to severely active disease.
Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in ...
Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...
Gram-negative bacteria, notorious for their intrinsic and acquired resistance mechanisms, pose a significant threat to public health. The emergence of ...
The FDA has approved Linzess (linaclotide) for treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older.
The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results